Qianjiang Yongan Pharmaceutical Co Ltd: A Focus on Taurine Production Amid Market Fluctuations

Qianjiang Yongan Pharmaceutical Co Ltd, a prominent player in the health care sector, continues to make strides in the pharmaceutical industry with its specialization in taurine production. The company, based in Qianjiang, China, is listed on the Shenzhen Stock Exchange and has been publicly traded since its IPO on March 5, 2010. As of April 24, 2025, the company’s close price stood at 11.85 CNH, with a 52-week high of 13.62 CNH and a low of 6.66 CNH recorded on September 17, 2024. The market capitalization is valued at 2,790,000,000 CNH, and the price-to-earnings ratio is 45.17.

Market Dynamics and Stock Performance

The broader market experienced fluctuations on April 24, 2025. The Shanghai Composite Index closed at 3297.29 points, marking a 0.93-point increase or a 0.03% rise. In contrast, the Shenzhen Component Index fell by 57.48 points to 9878.32, a 0.58% decrease. The ChiNext Index also saw a decline, dropping 13.30 points to 1935.86, a 0.68% fall. Amid these movements, 96 A-shares exhibited a turnover rate exceeding 20%, with notable activity in companies like C江顺科 and C天有, where turnover rates reached over 50%.

New Listings and Market Activity

The day also saw the listing of two new companies: N江顺科 and N天有. N江顺科 opened at 84.5 CNH per share, focusing on the development, design, production, and sales of aluminum extrusion molds and precision machine parts. N天有, with an opening price of 140 CNH per share, specializes in the development, production, and sales of automotive instruments, expanding into intelligent cockpit domains.

Sector Highlights and Trends

The market witnessed significant activity in various sectors. The PEEK materials concept saw a substantial rise, with stocks like 中欣氟材 and 新瀚新材 experiencing significant gains. The CRO concept also performed strongly, with 金凯生科 reaching a “20cm” increase, driven by a 41.83% rise in first-quarter revenue and a 183.24% increase in net profit.

The vitamin concept remained active, with stocks like 尔康制药 reaching a “20cm” increase, alongside 永安药业 and 河化股份. The lithium mining index also saw a near 2% rise, with 天齐锂业 and 永杉锂业 experiencing notable gains.

Investment and Dividend Insights

The market saw 39 stocks receiving leveraged capital purchases exceeding 5,000 million CNH, with 比亚迪 leading with a net purchase of 3.02 billion CNH. The mechanical equipment, telecommunications, and electronics sectors were particularly active in this regard.

Additionally, eight companies announced dividend implementation, with 股权登记日 on April 24. Notably, 龙迅股份 offered the highest dividend, with 7 CNH per 10 shares.

Corporate Announcements

On April 24, 20 companies announced shareholder reduction plans, with significant reduction ratios from companies like 英联股份, 多浦乐, and 锋龙股份.

Qianjiang Yongan Pharmaceutical Co Ltd continues to focus on its core business of taurine production, navigating the dynamic market conditions with strategic initiatives and maintaining its position in the pharmaceutical industry. For more information, visit their website at www.chinataurine.com .